Abstract
Epigenetic regulation has been shown to be involved in ferroptosis therapy resistance. Ferroptosis is
increasingly recognized as a promising treatment option for cancer therapy, while diagnostic tools that predict
tumor's sensitivity for ferroptosis are not yet developed. Therefore, in this industrial PhD project (Baekeland), a multi-step approach will
be applied to (i) identify a "ferroptomics" epifingerprint that determine this ferroptosis sensitivity, (ii) develop
a sensitive, cost-effective and portable nFERROCATCH assay to predict ferroptosis sensitivity based on TGS,
one of the strongholds of OHMX.bio (precision diagnostics based on Nanopore sequencing) and (iii) validate
the assay using experimental and clinical samples. This nFERROCATCH assay will be offered as a fee for
service and can also be further commercialized.
Researcher(s)
Research team(s)
Project type(s)